{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:29:07Z","timestamp":1790281747891,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04052-x","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:04:07Z","timestamp":1741665847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A systematic review of the role of interleukin-17 inhibitors in bullous pemphigoid: therapeutic and paradoxical effects"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-2270","authenticated-orcid":false,"given":"Seyedayin","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-8814","authenticated-orcid":false,"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-4066","authenticated-orcid":false,"given":"Yekta","family":"Ghane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-8895","authenticated-orcid":false,"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-1005","authenticated-orcid":false,"given":"Hamidreza","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"9","key":"4052_CR1","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/archderm.134.9.1075","volume":"134","author":"L Vaillant","year":"1998","unstructured":"Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C et al (1998) Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 134(9):1075\u20131080","journal-title":"Arch Dermatol"},{"issue":"2","key":"4052_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","volume":"94","author":"D Miyamoto","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW (2019) Bullous pemphigoid. An Bras Dermatol 94(2):133\u2013146","journal-title":"An Bras Dermatol"},{"issue":"9863","key":"4052_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381(9863):320\u2013332","journal-title":"Lancet"},{"issue":"4","key":"4052_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4103\/0019-5154.74534","volume":"55","author":"A De","year":"2010","unstructured":"De A, Rao R, Balachandran C (2010) Salt split technique: a useful tool in the diagnosis of subepidermal bullous disorders. Indian J Dermatol 55(4):334\u2013336","journal-title":"Indian J Dermatol"},{"key":"4052_CR5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/CCID.S267573","volume":"15","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Megna M, Villani A, Comune R, Fabbrocini G, di Vico F (2022) Strategies to improve outcomes of bullous pemphigoid: a comprehensive review of clinical presentations, diagnosis, and patients\u2019 assessment. Clin Cosmet Investig Dermatol 15:661\u2013673","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9","key":"4052_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1576","volume":"6","author":"S Sodagar","year":"2023","unstructured":"Sodagar S, Ghane Y, Heidari A, Heidari N, Khodadust E, Ahmadi SAY et al (2023) Association between metabolic syndrome and prevalent skin diseases: a systematic review and meta-analysis of case-control studies. Health Sci Rep 6(9):e1576","journal-title":"Health Sci Rep"},{"issue":"9","key":"4052_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","volume":"28","author":"PG Stavropoulos","year":"2014","unstructured":"Stavropoulos PG, Soura E, Antoniou C (2014) Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 28(9):1133\u20131140","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4052_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001642","author":"R Fatima","year":"2023","unstructured":"Fatima R, Altorok N (2023) Secukinumab-induced bullous pemphigoid in a patient with psoriatic arthritis. Am J Ther. https:\/\/doi.org\/10.1097\/MJT.0000000000001642","journal-title":"Am J Ther"},{"issue":"10","key":"4052_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/kjm2.12731","volume":"39","author":"YA Hsu","year":"2023","unstructured":"Hsu YA, Yang TT, Huang SM, Lan CE (2023) The effect of dipeptidyl peptidase-4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center. Kaohsiung J Med Sci 39(10):1038\u20131044","journal-title":"Kaohsiung J Med Sci"},{"issue":"7","key":"4052_CR10","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","volume":"33","author":"H Husein-ElAhmed","year":"2022","unstructured":"Husein-ElAhmed H, Steinhoff M (2022) Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. J Dermatolog Treat 33(7):2886\u20132893","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"4052_CR11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R et al (2022) Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 36(10):1689\u20131704","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4052_CR12","doi-asserted-by":"publisher","first-page":"1157250","DOI":"10.3389\/fimmu.2023.1157250","volume":"14","author":"M Oren-Shabtai","year":"2023","unstructured":"Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A et al (2023) Biological treatment for bullous pemphigoid. Front Immunol 14:1157250","journal-title":"Front Immunol"},{"issue":"12","key":"4052_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22912","volume":"9","author":"Y Ghane","year":"2023","unstructured":"Ghane Y, Heidari N, Heidari A, Sadeghi S, Goodarzi A (2023) Efficacy and safety of Bruton\u2019s tyrosine kinase inhibitors in the treatment of pemphigus: a comprehensive literature review and future perspective. Heliyon 9(12):e22912","journal-title":"Heliyon"},{"key":"4052_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jdin.2022.09.001","volume":"9","author":"A Abduelmula","year":"2022","unstructured":"Abduelmula A, Mufti A, Chong DHY, Sood S, Prajapati VH, Yeung J (2022) Biologic treatment outcomes in refractory bullous pemphigoid: an evidence-based review. JAAD Int 9:142\u2013145","journal-title":"JAAD Int"},{"key":"4052_CR15","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2147\/DDDT.S105263","volume":"10","author":"MI Koenders","year":"2016","unstructured":"Koenders MI, van den Berg WB (2016) Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Devel Ther 10:2069\u20132080","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"4052_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/1744666X.2019.1559730","volume":"15","author":"C Blegvad","year":"2019","unstructured":"Blegvad C, Skov L, Zachariae C (2019) Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Expert Rev Clin Immunol 15(2):111\u2013121","journal-title":"Expert Rev Clin Immunol"},{"issue":"10378","key":"4052_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG et al (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747\u2013761","journal-title":"Lancet"},{"key":"4052_CR18","unstructured":"National Heart, Lung, and Blood Institute (2014) Quality assessment tool for observational cohort and cross-sectional studies"},{"issue":"2","key":"4052_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23(2):60\u201363","journal-title":"BMJ Evid Based Med"},{"key":"4052_CR20","unstructured":"[NCT03099538] MC. Ixekizumab in the Treatment of Bullous Pemphigoid 2020 May; 21 https:\/\/clinicaltrials.gov\/study\/NCT03099538?cond=Bullous%20Pemphigoid&intr=ixekizumab&rank=1"},{"issue":"6","key":"4052_CR21","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1111\/jdv.18907","volume":"37","author":"K Bakirtzi","year":"2023","unstructured":"Bakirtzi K, Sotiriou E, Papadimitriou I, Vakirlis E, Delli FS, Ioannides D (2023) Anti-interleukin-17A biologics for the long-term treatment of bullous pemphigoid: a prospective, cohort study. J Eur Acad Dermatol Venereol 37(6):e749\u2013e751","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"4052_CR22","first-page":"1478","volume":"18","author":"MM Holtsche","year":"2020","unstructured":"Holtsche MM, Hammers CM, Chakievska L, Ludwig RJ, Thaci D, Zillikens D et al (2020) Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. J Dtsch Dermatol Ges 18(12):1478\u20131480","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"4052_CR23","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1111\/ajd.13803","volume":"63","author":"JS Yun","year":"2022","unstructured":"Yun JS, Scardamaglia L, Tan CG, McCormack CJ (2022) Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Australas J Dermatol 63(2):e155\u2013e158","journal-title":"Australas J Dermatol"},{"key":"4052_CR24","doi-asserted-by":"publisher","first-page":"1148660","DOI":"10.3389\/fmed.2023.1148660","volume":"10","author":"K Drenovska","year":"2023","unstructured":"Drenovska K, Valeva E, Shahid M, Vassileva S (2023) Case report: coexistence of bullous pemphigoid and psoriasis: therapeutic challenge and IL17A-targeted parallel treatment strategy. Front Med (Lausanne) 10:1148660","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4052_CR25","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.16189","volume":"49","author":"L Lu","year":"2022","unstructured":"Lu L, Yu Y, Zhang J, Fan X, Qi Y, Lin B (2022) Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis. J Dermatol 49(1):e13\u2013e15","journal-title":"J Dermatol"},{"issue":"2","key":"4052_CR26","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1111\/1346-8138.16559","volume":"50","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Gu Y, Xia D, Zhou X, Li W (2023) Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid. J Dermatol 50(2):e76\u2013e78","journal-title":"J Dermatol"},{"issue":"9","key":"4052_CR27","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1111\/1346-8138.13909","volume":"44","author":"PH Ho","year":"2017","unstructured":"Ho PH, Tsai TF (2017) Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol 44(9):e220\u2013e221","journal-title":"J Dermatol"},{"issue":"7","key":"4052_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/1346-8138.16765","volume":"50","author":"R Wang","year":"2023","unstructured":"Wang R, Wang A, Wang M (2023) Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: a paradoxical reaction. J Dermatol 50(7):956\u2013959","journal-title":"J Dermatol"},{"issue":"6","key":"4052_CR29","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1111\/1346-8138.16711","volume":"50","author":"N Sugihara","year":"2023","unstructured":"Sugihara N, Kamiya K, Nakano N, Suzuki M, Maekawa T, Murata S et al (2023) A case of bullous pemphigoid developing after ixekizumab therapy for pityriasis rubra pilaris. J Dermatol 50(6):e185\u2013e186","journal-title":"J Dermatol"},{"issue":"2","key":"4052_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/08820139.2020.1832113","volume":"51","author":"PS Tabatabaei-Panah","year":"2022","unstructured":"Tabatabaei-Panah PS, Moravvej H, Alirajab M, Etaaty A, Geranmayeh M, Hosseine F et al (2022) Association between TH2 cytokine gene polymorphisms and risk of bullous pemphigoid. Immunol Invest 51(2):343\u2013356","journal-title":"Immunol Invest"},{"issue":"12","key":"4052_CR31","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1007\/s12325-024-02992-w","volume":"41","author":"VP Werth","year":"2024","unstructured":"Werth VP, Murrell DF, Joly P, Heck R, Orengo JM, Ardeleanu M et al (2024) Pathophysiology of bullous pemphigoid: role of type 2 inflammation and emerging treatment strategies (narrative review). Adv Ther 41(12):4418\u20134432","journal-title":"Adv Ther"},{"issue":"1","key":"4052_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","volume":"143","author":"M Wakugawa","year":"2000","unstructured":"Wakugawa M, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H et al (2000) Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol 143(1):112\u2013116","journal-title":"Br J Dermatol"},{"key":"4052_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3389\/fimmu.2019.00701","volume":"10","author":"D Giusti","year":"2019","unstructured":"Giusti D, Bini E, Terryn C, Didier K, Le Jan S, Gatouillat G et al (2019) NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 interplay. Front Immunol 10:701","journal-title":"Front Immunol"},{"issue":"12","key":"4052_CR34","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","volume":"134","author":"S Le Jan","year":"2014","unstructured":"Le Jan S, Plee J, Vallerand D, Dupont A, Delanez E, Durlach A et al (2014) Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol 134(12):2908\u20132917","journal-title":"J Invest Dermatol"},{"issue":"5","key":"4052_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1046\/j.0022-202x.2001.01521.x","volume":"117","author":"S Verraes","year":"2001","unstructured":"Verraes S, Hornebeck W, Polette M, Borradori L, Bernard P (2001) Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 117(5):1091\u20131096","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4052_CR36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/jcm12010328","volume":"12","author":"CA Maronese","year":"2022","unstructured":"Maronese CA, Cassano N, Genovese G, Foti C, Vena GA, Marzano AV (2022) The intriguing links between psoriasis and bullous pemphigoid. J Clin Med 12(1):328","journal-title":"J Clin Med"},{"issue":"1","key":"4052_CR37","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1080\/07853890.2023.2188487","volume":"55","author":"F Chen","year":"2023","unstructured":"Chen F, Wang Y, Chen X, Yang N, Li L (2023) Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid. Ann Med 55(1):1156\u20131170","journal-title":"Ann Med"},{"issue":"1","key":"4052_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ajd.12899","volume":"60","author":"K Phan","year":"2019","unstructured":"Phan K, Goyal S, Murrell DF (2019) Association between bullous pemphigoid and psoriasis: systematic review and meta-analysis of case-control studies. Australas J Dermatol 60(1):23\u201328","journal-title":"Australas J Dermatol"},{"key":"4052_CR39","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","volume":"9","author":"MP Schon","year":"2018","unstructured":"Schon MP, Erpenbeck L (2018) The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol 9:1323","journal-title":"Front Immunol"},{"issue":"12","key":"4052_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1519","volume":"8","author":"PS Tabatabaei-Panah","year":"2020","unstructured":"Tabatabaei-Panah PS, Moravvej H, Aghaei S, Akbari M, Rajabi S, Kia A et al (2020) TH17\/IL23 cytokine gene polymorphisms in bullous pemphigoid. Mol Genet Genomic Med 8(12):e1519","journal-title":"Mol Genet Genomic Med"},{"key":"4052_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/967987","volume":"2013","author":"A Zebrowska","year":"2013","unstructured":"Zebrowska A, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska-Kanicka O, Cynkier A, Sysa-Jedrzejowska A et al (2013) IL-17 expression in dermatitis herpetiformis and bullous pemphigoid. Mediators Inflamm 2013:967987","journal-title":"Mediators Inflamm"},{"key":"4052_CR42","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/srep18001","volume":"5","author":"J Plee","year":"2015","unstructured":"Plee J, Le Jan S, Giustiniani J, Barbe C, Joly P, Bedane C et al (2015) Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep 5:18001","journal-title":"Sci Rep"},{"key":"4052_CR43","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3389\/fimmu.2019.02107","volume":"10","author":"S Nesmond","year":"2019","unstructured":"Nesmond S, Muller C, Le Naour R, Viguier M, Bernard P, Antonicelli F et al (2019) Characteristic pattern of IL-17RA, IL-17RB, and IL-17RC in monocytes\/macrophages and mast cells from patients with bullous pemphigoid. Front Immunol 10:2107","journal-title":"Front Immunol"},{"key":"4052_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050373","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wang S-H, Zuo Y-G (2023) Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1050373","journal-title":"Front Immunol"},{"issue":"4","key":"4052_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1365-2133.1998.02169.x","volume":"138","author":"F Ameglio","year":"1998","unstructured":"Ameglio F, D\u2019Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B (1998) Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol 138(4):611\u2013614","journal-title":"Br J Dermatol"},{"issue":"4","key":"4052_CR46","first-page":"148","volume":"11","author":"F Ameglio","year":"1997","unstructured":"Ameglio F, D\u2019Auria L, Cordiali-Fei P, Mussi A, Valenzano L, D\u2019Agosto G et al (1997) Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J Biol Regul Homeost Agents 11(4):148\u2013153","journal-title":"J Biol Regul Homeost Agents"},{"issue":"4","key":"4052_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.mehy.2009.10.038","volume":"74","author":"S Toosi","year":"2010","unstructured":"Toosi S, Bystryn JC (2010) Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid. Med Hypotheses 74(4):727\u2013728","journal-title":"Med Hypotheses"},{"key":"4052_CR48","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3389\/fimmu.2019.01972","volume":"10","author":"S Le Jan","year":"2019","unstructured":"Le Jan S, Muller C, Plee J, Durlach A, Bernard P, Antonicelli F (2019) IL-23\/IL-17 axis activates IL-1beta-associated inflammasome in macrophages and generates an auto-inflammatory response in a subgroup of patients with bullous pemphigoid. Front Immunol 10:1972","journal-title":"Front Immunol"},{"key":"4052_CR49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","volume":"96","author":"L Chakievska","year":"2019","unstructured":"Chakievska L, Holtsche MM, Kunstner A, Goletz S, Petersen BS, Thaci D et al (2019) IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 96:104\u2013112","journal-title":"J Autoimmun"},{"issue":"4","key":"4052_CR50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.36290\/vnl.2021.052","volume":"67","author":"K Pavelka","year":"2021","unstructured":"Pavelka K (2021) Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. Vnitr Lek 67(4):195\u2013200","journal-title":"Vnitr Lek"},{"key":"4052_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/ITT.S259126","volume":"10","author":"F Atzeni","year":"2021","unstructured":"Atzeni F, Carriero A, Boccassini L, D\u2019Angelo S (2021) Anti-IL-17 agents in the treatment of axial spondyloarthritis. Immunotargets Ther 10:141\u2013153","journal-title":"Immunotargets Ther"},{"issue":"6","key":"4052_CR52","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1111\/1346-8138.14760","volume":"46","author":"M Kamata","year":"2019","unstructured":"Kamata M, Asano Y, Shida R, Maeda N, Yoshizaki A, Miyagaki T et al (2019) Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. J Dermatol 46(6):e216\u2013e217","journal-title":"J Dermatol"},{"issue":"5","key":"4052_CR53","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/jdv.14002","volume":"31","author":"J Loget","year":"2017","unstructured":"Loget J, Plee J, Antonicelli F, Bernard P (2017) A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol 31(5):e228\u2013e230","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"4052_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1346-8138.2012.01659.x","volume":"40","author":"M Nin","year":"2013","unstructured":"Nin M, Tokunaga D, Ishii N, Komai A, Hashimoto T, Katoh N (2013) Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol 40(1):55\u201356","journal-title":"J Dermatol"},{"issue":"11","key":"4052_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1365-4632.2006.02861.x","volume":"45","author":"A Wilczek","year":"2006","unstructured":"Wilczek A, Sticherling M (2006) Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship? Int J Dermatol 45(11):1353\u20131357","journal-title":"Int J Dermatol"},{"issue":"2","key":"4052_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2020.05.010","volume":"100","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wang G (2020) Genetic predisposition to bullous pemphigoid. J Dermatol Sci 100(2):86\u201391","journal-title":"J Dermatol Sci"},{"issue":"1","key":"4052_CR57","first-page":"1","volume":"10","author":"N Esmaili","year":"2013","unstructured":"Esmaili N, Mortazavi H, Chams-Davatchi C, Daneshpazhooh M, Damavandi MR, Aryanian Z et al (2013) Association between HLA-DQB1*03:01 and Bullous pemphigoid in Iranian patients. Iran J Immunol 10(1):1\u20139","journal-title":"Iran J Immunol"},{"issue":"3","key":"4052_CR58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1346-8138.2000.tb02141.x","volume":"27","author":"A Okazaki","year":"2000","unstructured":"Okazaki A, Miyagawa S, Yamashina Y, Kitamura W, Shirai T (2000) Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid. J Dermatol 27(3):149\u2013156","journal-title":"J Dermatol"},{"issue":"1","key":"4052_CR59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.autrev.2011.07.002","volume":"11","author":"LR Zakka","year":"2011","unstructured":"Zakka LR, Reche P, Ahmed AR (2011) Role of MHC Class II genes in the pathogenesis of pemphigoid. Autoimmun Rev 11(1):40\u201347","journal-title":"Autoimmun Rev"},{"issue":"2","key":"4052_CR60","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2249.2010.04239.x","volume":"162","author":"LR Zakka","year":"2010","unstructured":"Zakka LR, Keskin DB, Reche P, Ahmed AR (2010) Relationship between target antigens and major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously. Clin Exp Immunol 162(2):224\u2013236","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"4052_CR61","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/ddg.13182","volume":"15","author":"M Rychlik-Sych","year":"2017","unstructured":"Rychlik-Sych M, Bara\u0144ska M, Dudarewicz M, Skr\u0119tkowicz J, \u017bebrowska A, Owczarek J et al (2017) ABCB1 gene is associated with the risk of bullous pemphigoid in a polish population. J Deutsche Derma Gesell 15(5):499\u2013505","journal-title":"J Deutsche Derma Gesell"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04052-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04052-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:53:42Z","timestamp":1741848822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04052-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4052"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04052-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"544"}}